• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Hricak Hedvig

    2/7/25 4:06:22 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care
    Get the next $ICAD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hricak Hedvig

    (Last) (First) (Middle)
    C/O ICAD, INC.
    98 SPIT BROOK ROAD, SUITE 100

    (Street)
    NASHUA NH 03062

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ICAD INC [ ICAD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Director Stock Option (right to buy) $3.69 02/05/2025 A 6,641 (1) 02/05/2035 Common Stock 6,641 $0.00 6,641 D
    Explanation of Responses:
    1. This option has been granted in lieu of quarterly cash director fees. The option is immediately exercisable on the date of grant.
    /s/ Hedvig Hricak 02/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ICAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICAD

    DatePrice TargetRatingAnalyst
    4/17/2025Buy → Neutral
    BTIG Research
    4/17/2025Buy → Hold
    Laidlaw
    1/18/2022Buy → Neutral
    Guggenheim
    1/5/2022$22.00 → $16.00Outperform
    Oppenheimer
    11/10/2021$22.00 → $18.00Market Outperform
    JMP Securities
    More analyst ratings

    $ICAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

      NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

      5/13/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is to enhance the capabilities of healthcare professionals. Momentum in this space is being driven by recent initiatives from companies like Avant Technologies, Inc. (OTCQB:AVAI), Koninklijke Philips N.V. (NYSE:PHG), HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF), RadNet, Inc. (NASDAQ:RDNT)

      4/29/25 11:10:00 AM ET
      $ICAD
      $PHG
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Electronics
      Medical Specialities
    • iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft's Precision Imaging Network (PIN)

      NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD's ProFound Breast Health Suite on Microsoft's Precision Imaging Network. The iCAD and Microsoft collaboration provides access to automated radiology mammography reporting for patients through Microsoft's advanced radiology reporting platform, PowerScribe. iCAD's ProFound AI® Breast Health Suite will be fully cloud-hosted across Microsoft's extensive network, providing radiologists and healthcare providers wit

      4/29/25 8:00:00 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Leadership Updates

    Live Leadership Updates

    See more
    • iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

      NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnersh

      4/8/25 10:19:01 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

      NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C

      2/27/24 9:05:00 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

      NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare executive with over 35 years of experience. He is currently the CEO of Spire Health, a leading healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire along with Mr. Doyle's recent companies all achieved measu

      1/30/24 8:00:00 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iCAD downgraded by BTIG Research

      BTIG Research downgraded iCAD from Buy to Neutral

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD downgraded by Laidlaw

      Laidlaw downgraded iCAD from Buy to Hold

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • icad downgraded by Guggenheim

      Guggenheim downgraded icad from Buy to Neutral

      1/18/22 7:19:48 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

      SC 13G/A - ICAD INC (0000749660) (Subject)

      2/14/24 9:00:29 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

      SC 13G/A - ICAD INC (0000749660) (Subject)

      7/24/23 3:59:05 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by iCAD Inc.

      SC 13G - ICAD INC (0000749660) (Subject)

      3/15/23 3:15:23 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Brown Dana R gave a grant of 11,483 shares, decreasing direct ownership by 17% to 54,350 units (SEC Form 4)

      4 - ICAD INC (0000749660) (Issuer)

      4/16/25 9:50:42 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Officer Lonnqvist Eric gave a grant of 7,345 shares, decreasing direct ownership by 46% to 8,488 units (SEC Form 4)

      4 - ICAD INC (0000749660) (Issuer)

      4/16/25 9:50:12 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Officer Brown Dana R was granted 25,833 shares, increasing direct ownership by 65% to 65,833 units (SEC Form 4)

      4 - ICAD INC (0000749660) (Issuer)

      2/27/25 9:55:47 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    SEC Filings

    See more
    • SEC Form 10-Q filed by iCAD Inc.

      10-Q - ICAD INC (0000749660) (Filer)

      5/13/25 4:33:34 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form 425 filed by iCAD Inc.

      425 - ICAD INC (0000749660) (Subject)

      5/13/25 4:11:42 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ICAD INC (0000749660) (Filer)

      5/13/25 4:11:17 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Financials

    Live finance-specific insights

    See more
    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

      NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

      5/13/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

      The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligenceFollowing the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutionsRadNet will host a conference call and

      4/15/25 4:01:37 PM ET
      $ICAD
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024

      NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenues increased 14% to $5.4 millionGross Profit Margin of 86%382 Total deals closed in 2024, 42 of which were ProFound CloudProFound Detection V4.0 granted FDA clearanceExpanded global reach with ne

      3/19/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care